Paragon 28®, Inc. was established in 2010 to address the unmet and under-served needs of the foot and ankle community. From the onset, Paragon 28® has made it its goal to re-invent the space of foot and ankle surgery. The companies believes that through research and innovation Paragon can create new and improved solutions to the challenges faced by foot and ankle specialists.
Company profile
Ticker
FNA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
Corporate docs
IRS number
273170186
FNA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
30 Jan 23
424B5
Prospectus supplement for primary offering
27 Jan 23
424B5
Prospectus supplement for primary offering
25 Jan 23
8-K
Results of Operations and Financial Condition
25 Jan 23
8-K
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
10 Jan 23
8-K
Entry into a Material Definitive Agreement
1 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
10 Nov 22
EFFECT
Notice of effectiveness
8 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
Latest ownership filings
4
Albert DaCosta
1 Feb 23
3
B. AG Bird
12 Jan 23
SC 13G
Bird B. AG
12 Jan 23
4
Matthew Jarboe
27 Dec 22
4
Matthew Jarboe
23 Dec 22
4
Change in insider ownership
21 Dec 22
4
Change in insider ownership
15 Dec 22
4
Change in insider ownership
12 Dec 22
4
Albert DaCosta
2 Dec 22
4
Change in insider ownership
2 Dec 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 56.33 mm | 56.33 mm | 56.33 mm | 56.33 mm | 56.33 mm | 56.33 mm |
Cash burn (monthly) | 5.56 mm | (no burn) | 3.17 mm | 2.85 mm | (no burn) | 888.17 k |
Cash used (since last report) | 23.47 mm | n/a | 13.40 mm | 12.02 mm | n/a | 3.75 mm |
Cash remaining | 32.86 mm | n/a | 42.92 mm | 44.31 mm | n/a | 52.58 mm |
Runway (months of cash) | 5.9 | n/a | 13.5 | 15.6 | n/a | 59.2 |
Institutional ownership, Q3 2022
68.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 79 |
Opened positions | 18 |
Closed positions | 7 |
Increased positions | 29 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 964.34 mm |
Total shares | 52.91 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bird B. | 15.55 mm | $275.10 mm |
MVM Partners | 14.41 mm | $281.37 mm |
Rosenthal Investment | 7.21 mm | $127.62 mm |
BLK Blackrock | 2.54 mm | $45.29 mm |
Wasatch Advisors | 1.71 mm | $30.41 mm |
Vanguard | 1.39 mm | $24.69 mm |
First Light Asset Management | 1.24 mm | $22.06 mm |
BAC Bank Of America | 1.10 mm | $19.52 mm |
ArrowMark Colorado | 819.03 k | $14.60 mm |
Skandinaviska Enskilda Banken AB | 780.57 k | $13.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jan 23 | Albert DaCosta | Common Stock | Sell | Dispose S | Yes | No | 0 | 500,000 | 0.00 | 100,000 |
30 Jan 23 | Albert DaCosta | Common Stock | Sell | Dispose S | No | No | 17 | 500,000 | 8.50 mm | 479,136 |
17 Jan 23 | Albert DaCosta | Common Stock | Other | Dispose J | Yes | No | 0 | 1,200,000 | 0.00 | 5,280,610 |
23 Dec 22 | Matthew Jarboe | Common Stock | Sell | Dispose S | No | Yes | 20.9253 | 35,110 | 734.69 k | 271,764 |
23 Dec 22 | Matthew Jarboe | Common Stock | Option exercise | Acquire M | No | No | 1.2 | 35,110 | 42.13 k | 306,874 |
23 Dec 22 | Matthew Jarboe | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.2 | 35,110 | 42.13 k | 25,000 |
21 Dec 22 | Matthew Jarboe | Common Stock | Sell | Dispose S | No | Yes | 20.9132 | 24,913 | 521.01 k | 271,764 |
21 Dec 22 | Matthew Jarboe | Common Stock | Option exercise | Acquire M | No | No | 1.2 | 14,890 | 17.87 k | 296,677 |
21 Dec 22 | Matthew Jarboe | Common Stock | Option exercise | Acquire M | No | No | 0.6 | 10,023 | 6.01 k | 281,787 |
21 Dec 22 | Matthew Jarboe | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.2 | 14,890 | 17.87 k | 60,110 |
News
Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
26 Jan 23
12 Health Care Stocks Moving In Thursday's Intraday Session
26 Jan 23
12 Health Care Stocks Moving In Thursday's Pre-Market Session
26 Jan 23
Reported Late Wednesday, Paragon 28 Announces Pricing Of $63.8M Public Offering Of $6.5M Shares Of Common Stock At A Price Of $17/Share
26 Jan 23
12 Health Care Stocks Moving In Wednesday's After-Market Session
25 Jan 23
Press releases
Paragon 28, Inc. Announces Pricing of Public Offering
25 Jan 23
Paragon 28, Inc. Announces Proposed Public Offering of Common Stock
25 Jan 23
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
10 Jan 23
Paragon 28 to Present at The 34th Annual Piper Sandler Healthcare Conference
16 Nov 22
Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
10 Nov 22